Your browser doesn't support javascript.
loading
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs, Matthew C; Burn, Timothy C; Sparks, Richard; Maduskuie, Thomas; Diamond, Sharon; Rupar, Mark; Wen, Xiaoming; Volgina, Alla; Zolotarjova, Nina; Waeltz, Paul; Favata, Margaret; Jalluri, Ravi; Liu, Huiqing; Liu, Xuesong Mike; Li, Jun; Collins, Robert; Falahatpisheh, Nikoo; Polam, Padmaja; DiMatteo, Darlise; Feldman, Patricia; Dostalik, Valerie; Thekkat, Pramod; Gardiner, Christine; He, Xin; Li, Yanlong; Covington, Maryanne; Wynn, Richard; Ruggeri, Bruce; Yeleswaram, Swamy; Xue, Chu-Biao; Yao, Wenqing; Combs, Andrew P; Huber, Reid; Hollis, Gregory; Scherle, Peggy; Liu, Phillip C C.
Afiliación
  • Stubbs MC; Incyte Corporation, Wilmington, Delaware. mstubbs@incyte.com pliu@incyte.com.
  • Burn TC; Incyte Corporation, Wilmington, Delaware.
  • Sparks R; Incyte Corporation, Wilmington, Delaware.
  • Maduskuie T; Incyte Corporation, Wilmington, Delaware.
  • Diamond S; Incyte Corporation, Wilmington, Delaware.
  • Rupar M; Incyte Corporation, Wilmington, Delaware.
  • Wen X; Incyte Corporation, Wilmington, Delaware.
  • Volgina A; Incyte Corporation, Wilmington, Delaware.
  • Zolotarjova N; Incyte Corporation, Wilmington, Delaware.
  • Waeltz P; Incyte Corporation, Wilmington, Delaware.
  • Favata M; Incyte Corporation, Wilmington, Delaware.
  • Jalluri R; Incyte Corporation, Wilmington, Delaware.
  • Liu H; Incyte Corporation, Wilmington, Delaware.
  • Liu XM; Incyte Corporation, Wilmington, Delaware.
  • Li J; Incyte Corporation, Wilmington, Delaware.
  • Collins R; Incyte Corporation, Wilmington, Delaware.
  • Falahatpisheh N; Incyte Corporation, Wilmington, Delaware.
  • Polam P; Incyte Corporation, Wilmington, Delaware.
  • DiMatteo D; Incyte Corporation, Wilmington, Delaware.
  • Feldman P; Incyte Corporation, Wilmington, Delaware.
  • Dostalik V; Incyte Corporation, Wilmington, Delaware.
  • Thekkat P; Incyte Corporation, Wilmington, Delaware.
  • Gardiner C; Incyte Corporation, Wilmington, Delaware.
  • He X; Incyte Corporation, Wilmington, Delaware.
  • Li Y; Incyte Corporation, Wilmington, Delaware.
  • Covington M; Incyte Corporation, Wilmington, Delaware.
  • Wynn R; Incyte Corporation, Wilmington, Delaware.
  • Ruggeri B; Incyte Corporation, Wilmington, Delaware.
  • Yeleswaram S; Incyte Corporation, Wilmington, Delaware.
  • Xue CB; Incyte Corporation, Wilmington, Delaware.
  • Yao W; Incyte Corporation, Wilmington, Delaware.
  • Combs AP; Incyte Corporation, Wilmington, Delaware.
  • Huber R; Incyte Corporation, Wilmington, Delaware.
  • Hollis G; Incyte Corporation, Wilmington, Delaware.
  • Scherle P; Incyte Corporation, Wilmington, Delaware.
  • Liu PCC; Incyte Corporation, Wilmington, Delaware. mstubbs@incyte.com pliu@incyte.com.
Clin Cancer Res ; 25(1): 300-311, 2019 01 01.
Article en En | MEDLINE | ID: mdl-30206163
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Compuestos Orgánicos / Factores de Transcripción / Proteínas de Ciclo Celular / Receptores de Interleucina-6 / Factor de Transcripción STAT3 / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Compuestos Orgánicos / Factores de Transcripción / Proteínas de Ciclo Celular / Receptores de Interleucina-6 / Factor de Transcripción STAT3 / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2019 Tipo del documento: Article